Specialist Referral Improved Cholesterol Control in Prostate Cancer

Evidence

Routine referral to an adult-medicine or heart specialist improved cholesterol control in patients with prostate cancer, but did not demonstrate fewer major cardiovascular events.

Published November 1, 2026, the Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer trial was a randomized study designed to evaluate a strategy in routine care. Across 55 sites in eight countries, a computer-generated schedule assigned 2,501 patients to usual care or usual care plus routine referral to an internist or cardiologist. The analysis included 2,487 patients.

Participants had been diagnosed within the previous 12 months, had first received androgen deprivation therapy—a hormone-suppressing treatment—within six months, or planned to start it within one month. Specialists used a systematic strategy combining blood-pressure management, cholesterol-lowering statin medication regardless of starting cholesterol, and smoking-cessation, diet and exercise guidance.

Over a median follow-up of 5.8 years:

- The combined outcome favored referral. It ranked cardiovascular death, heart attack, stroke, heart failure, inadequate cholesterol control and inadequate blood-pressure control in priority order. The win ratio, which compares outcomes between groups using that hierarchy, was 1.60. Its 95% confidence interval—a measure of statistical uncertainty—was 1.42–1.81. Values above 1 favor referral, but this does not mean 60% fewer cardiovascular events. The advantage was mostly attributable to lower cholesterol and greater protocol-mandated statin use. - Cholesterol was lower with referral. The mean difference was 12 milligrams per deciliter, with a 95% confidence interval of 9–15 milligrams per deciliter. - The clinical-event comparison did not demonstrate a difference. For time to cardiovascular death, heart attack, stroke or heart failure, the subdistribution hazard ratio was 1.08, with a 95% confidence interval of 0.79–1.49. This measure compares event occurrence over time while accounting for other events that can prevent the outcome; 1 represents no difference.

Analysis

Interpretation: The strongest supported conclusion concerns risk-factor management, particularly cholesterol control. A favorable combined outcome that includes both clinical events and risk-factor measurements does not establish fewer deaths, heart attacks, strokes or heart-failure events.

Randomization strengthens the comparison of the overall referral strategy with usual care. It does not identify which component of that strategy produced the cholesterol difference. This is a single-study report, not independent confirmation across studies.

Limitations

Cardiovascular events were less common than expected, limiting the trial’s ability to detect clinical differences. Some usual-care participants adopted intervention components, while some intervention participants did not follow the strategy; both reduced the contrast between groups.

The clinical-event uncertainty interval leaves meaningful benefit or harm unresolved. Failure to demonstrate a difference is therefore not proof that referral has no clinical effect. Likewise, a statistically clear cholesterol difference does not establish a clinically important reduction in cardiovascular events.

What to watch

Confidence in clinical benefit would increase if a randomized comparison with enough cardiovascular events and documented separation in treatment use found fewer cardiovascular deaths, heart attacks, strokes or heart-failure events with referral, with uncertainty narrow enough to exclude no benefit.